IMPAIRED SHP2-MEDIATED ERK ACTIVATION CONTRIBUTES TO GEFITINIB SENSITIVITY OF LUNG CANCER CELLS WITH EGFR-ACTIVATING MUTATIONS

Most non-small cell lung cancers (NSCLC) display elevated expression of epidermal growth factor receptor (EGFR), but response to EGFR kinase inhibitors is predominantly limited to NSCLC harboring EGFR-activating mutations. These mutations are associated with increased activity of survival pathways including PI3K/AKT and STAT3/5. We report that EGFR-activating mutations also surprisingly lead to decreased ability to activate ERK compared to wild-type EGFR. In NSCLC cells and mouse embryonic fibroblasts expressing mutant EGFR, this effect on ERK correlates with decreased EGFR internalization and reduced phosphorylation of SHP2, a tyrosine phosphatase required for the full activation of ERK. We further demonstrate that ERK activation levels impact cellular response to gefitinib. NSCLC cells with EGFR mutation display reduced gefitinib sensitivity when ERK activation is augmented by expression of constitutively active mutants of MEK. Conversely, in an NSCLC cell line expressing wild-type EGFR, gefitinib treatment along with or following MEK inhibition increases death response compared to treatment with gefitinib alone. Our results demonstrate that EGFR-activating mutations may promote some survival pathways but simultaneously impair others. This multivariate alteration of the network governing cellular response to gefitinib, which we term “oncogene imbalance”, portends a potentially broader ability to treat gefitinib-resistant NSCLC.

[1]  M. Loda,et al.  Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non–Small-Cell Lung Cancer , 2009, Clinical Cancer Research.

[2]  W. Pao,et al.  KRAS mutations in non-small cell lung cancer. , 2009, Proceedings of the American Thoracic Society.

[3]  M. Meyerson,et al.  The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP , 2008, Proceedings of the National Academy of Sciences.

[4]  Y. Yatabe,et al.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer , 2007, Cancer science.

[5]  Eric S. Lander,et al.  Integrative Genomic Approaches Identify IKBKE as a Breast Cancer Oncogene , 2007, Cell.

[6]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[7]  Roy S Herbst,et al.  KRAS Mutation Is an Important Predictor of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer , 2007, Clinical Cancer Research.

[8]  Levi A Garraway,et al.  Mutations in BRAF and KRAS converge on activation of the mitogen-activated protein kinase pathway in lung cancer mouse models. , 2007, Cancer research.

[9]  Matthew Meyerson,et al.  Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. , 2007, Cancer cell.

[10]  D. Haber,et al.  Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  B. Neel,et al.  The role of Shp2 (PTPN11) in cancer. , 2007, Current opinion in genetics & development.

[12]  W. Pao,et al.  Update on Epidermal Growth Factor Receptor Mutations in Non–Small Cell Lung Cancer , 2006, Clinical Cancer Research.

[13]  D. Haber,et al.  A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. , 2006, Cancer cell.

[14]  G J Griffiths,et al.  Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib. , 2006, Systems biology.

[15]  J. Yokota,et al.  Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells. , 2006, Lung cancer.

[16]  Stuart Thomson,et al.  Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. , 2006, Cancer research.

[17]  N. Rosen,et al.  Association with HSP90 inhibits Cbl-mediated down-regulation of mutant epidermal growth factor receptors. , 2006, Cancer research.

[18]  John Kuriyan,et al.  An Allosteric Mechanism for Activation of the Kinase Domain of Epidermal Growth Factor Receptor , 2006, Cell.

[19]  J. Minna,et al.  Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. , 2006, Cancer research.

[20]  C. Mermel,et al.  ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[21]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[22]  H. Varmus,et al.  KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib , 2005, PLoS medicine.

[23]  Takayuki Kosaka,et al.  Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.

[24]  Matthew Meyerson,et al.  Gefitinib Induces Apoptosis in the EGFRL858R Non–Small-Cell Lung Cancer Cell Line H3255 , 2004, Cancer Research.

[25]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Daniel A. Haber,et al.  Gefitinib-Sensitizing EGFR Mutations in Lung Cancer Activate Anti-Apoptotic Pathways , 2004, Science.

[27]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[28]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[29]  B. Neel,et al.  Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. , 2004, Molecular cell.

[30]  B. Neel,et al.  Tyrosyl Phosphorylation of Shp2 Is Required for Normal ERK Activation in Response to Some, but Not All, Growth Factors* , 2003, Journal of Biological Chemistry.

[31]  M. Whiteway,et al.  Negative Regulation of MAPKK by Phosphorylation of a Conserved Serine Residue Equivalent to Ser212 of MEK1* , 2003, The Journal of Biological Chemistry.

[32]  Douglas Lauffenburger,et al.  Coregulation of epidermal growth factor receptor/human epidermal growth factor receptor 2 (HER2) levels and locations: quantitative analysis of HER2 overexpression effects. , 2003, Cancer research.

[33]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[34]  P. Bunn,et al.  ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. , 2002, Seminars in oncology.

[35]  S. Schmid,et al.  Control of EGF Receptor Signaling by Clathrin-Mediated Endocytosis , 1996, Science.

[36]  M. Gossen,et al.  Tightly regulated and inducible expression of dominant interfering dynamin mutant in stably transformed HeLa cells. , 1995, Methods in enzymology.

[37]  H. Wiley,et al.  Quantitative analysis of the endocytic system involved in hormone-induced receptor internalization. , 1990, The Journal of biological chemistry.